SR @PatternNotes
🧩Educational discussion of historical market structure & liquidity. No buy/sell/hold recommendations. Liquidity ≠ prediction. Not signals. Not financial advice Joined October 2021-
Tweets2K
-
Followers201
-
Following782
-
Likes239
Just signed up. I know that does not solve the bigger economics, but I wanted to support the work because your voice is original and the DD has real depth. The quick-returns crowd is loud, but some of us are here for the opposite: under-the-radar names, longer-duration setups, and frameworks we would not have found on our own. That is the edge. I hope you keep posting in whatever form still makes sense for you.
In other words: potential blockbuster. Not because it lowers LDL alone. Because if the outcomes data confirm the signal, $NAMS may hit LDL, Lp(a), glycemic risk, small-particle biology, and brain-aging biomarkers in one oral drug. Long $NAMS. My personal notes. Not financial advice.
@Hstlinghosptlis @JoshuaBarzon @official_flo @FLAGALine @Floridaman @nbc6 @RonDeSantis @SunSentinel @FloridaTourism @FlaPanthers @FloridaGators Food options good? Beach 🏖️? Clearwater best beach I have seen, how does it compare? Thanks
@BiomedicalRX @meremrtl No PhD here, but I grew up watching my father chase one in chemical engineering, and that shaped how I think.
I don’t own $ABVX, but this biology is fascinating. Whether obefazimod becomes first-line, second-line, or third-line in UC clearly matters commercially. But my bigger question is biological: Is $ABVX touching a real immune-dose lever? Bullish defense: the short parent-drug half-life is a relief. Obefazimod itself clears quickly. But the active metabolite, ABX464-N-Glu, appears to have a much longer half-life and is also pharmacologically active. So the question is not simply: “Could a short half-life drug create cancer in under a year?” The better question is whether chronic miR-124 pathway tuning changes immune signal-to-noise over time. Too much inflammation can become biological noise. Too much immune dampening may reduce surveillance. Looking at the 25 mg and 50 mg cohorts makes you wonder: Maybe 25 mg is the Goldilocks dose. Maybe the true immune-modulation window is even lower. Completely unproven — but this is the question the safety debate opens up. Purely a mechanistic hypothesis — not medical or financial advice.
@Hstlinghosptlis @JoshuaBarzon @official_flo @FLAGALine @Floridaman @nbc6 @RonDeSantis @SunSentinel @FloridaTourism @FlaPanthers @FloridaGators Why? 30A/Santa Rosa Beach is hard to beat — Seaside, Grayton, Rosemary, white-sand beaches, slower pace, and enough good food without the Orlando/Miami chaos?
This is why the dose-escalation data matters so much: it is not just about Wilson disease — it is about whether PRME’s liver-editing chassis can become reusable. Prime building a printer? Printer = GalNAc liver LNP + Prime Editor system File = pegRNA / nicking guide RNA Document = corrected liver gene Wilson disease is the first liver document. AATD is the second. GSD1b is the third. If every document needs a brand-new printer, the business is weaker. But if the printer largely stays the same and only the file changes, the platform becomes much more valuable. Scenario math — personal estimates, not company guidance: CGD: $100M–$400M peak annual potential as a human Prime Editing validation bridge Wilson: $500M–$1.5B peak annual potential AATD: $1B–$4B+ peak annual potential Other liver documents: $100M–$500M each Platform / partnering value: meaningful optionality If the printer works safely in humans, the revenue math stops being “one rare disease” and becomes: How many liver mutations can this system print? My personal notes. Not financial advice. No current PRME position; watching closely.
@LennaertSnyder @WatcherGuru For now, I’m currently net short BTC, but my bias is flexible and may flip long if liquidity/structure changes. My personal notes. Not financial advice.
@LennaertSnyder @WatcherGuru Jusy having fun. 64.5k is what i am watching. Lets see if there is any bounce left? My personal notes. Not financial advice
@LennaertSnyder @WatcherGuru You mean 64,5k? Lol
Agree with this. OA desperately needs something beyond pain management, injections, and eventual joint replacement. GLP-1s may already be helping the load/inflammation side, and Cartigenix HP/RestorCel has interesting joint-biomarker data, but neither is the same as rebuilding lost joint architecture. If the animal regeneration signal translates into durable human cartilage/bone repair, that could be a totally different category for orthopedics. Thanks for sharing
Disclosure: I’m long CRBU. This is my personal thesis based on public information only. High-risk biotech. Not financial advice. I may add, trim, or exit as facts or risk change.
The market is Wonderland. 🕰️🐇 Sometimes you have to believe in six impossible things before the opening bell rings. Impossible thing number two: The four-lane CRBU thesis The market may be missing the real CRBU structure. Caribou is not only two clinical drugs. It may be two clinical drugs plus a licensable editing architecture. CB-010 / vispa-cel has shown 82% ORR, 64% CR, and 51% PFS at 12 months in the prospectively HLA-matched confirmatory cohort. CB-011 has shown 92% ORR, 75% ≥CR, and 91% MRD negativity in early CaMMouflage data, and now has RMAT designation. Those are the clinical proof points. But chRDNA is the platform layer. Caribou invented CRISPR hybrid RNA-DNA guides to improve editing specificity and support precise, complex genome edits for off-the-shelf cell therapies. That creates a possible tollbooth model: • ex vivo CD19 drug rights • ex vivo BCMA drug rights • CD19-related platform / future modality rights • BCMA-related platform / future modality rights The FDA Platform Technology Designation Program makes this more interesting, because validated platform technologies may be able to leverage prior CMC/safety/manufacturing data across related products. But the key is rights of reference. Nobody gets to use CRBU’s platform data for free. They would need to license the IP and the data rights. That is the bull case: CB-010 and CB-011 validate the clinical layer. chRDNA becomes the licensable infrastructure layer. If Big Pharma wants the drug, they pay for the drug. If Big Pharma wants the editing architecture for future ex vivo or in vivo programs, they may need to pay again. That is the four-lane CRBU thesis. 1. Ex Vivo CD19 — CB-010 / vispa-cel Big Pharma pays for the mature, clinical-stage, off-the-shelf CD19 CAR-T asset to secure lymphoma optionality. 2. Ex Vivo BCMA — CB-011 Big Pharma pays for the RMAT-designated BCMA CAR-T asset to secure multiple myeloma optionality. 3. In Vivo CD19 — Platform License Big Pharma pays for chRDNA “scissors,” IP access, and potential rights of reference to relevant platform data for future CD19 in vivo or autoimmune applications like lupus. 4. In Vivo BCMA — Platform License Big Pharma pays for chRDNA “scissors,” IP access, and potential rights of reference to relevant platform data for future BCMA in vivo or next-generation myeloma programs. My personal notes. Not financial advice
DNA contains the IL15 gene → the cell transcribes it into IL15 mRNA → ribosomes translate that mRNA into IL-15 protein → IL-15 is used locally or presented/released to communicate with immune cells. Skeletal muscle can express that gene, especially in the context of contraction and exercise stress. The muscle then uses IL-15 as a myokine — a message to the immune system. That message helps support NK cells and CD8+ T cells, which are central to immune surveillance. Exercise turns on the IL-15 message; redox/persulfidation support may reduce inflammatory static so the immune system hears that message more clearly. High inflammation = static on the radio. Exercise = the broadcast. IL-15 = one of the key messages. Redox support = reducing the static so the message comes through cleaner. Immune labs: 1. Lymphocyte subset panel This is the first real “under the hood” immune panel. It breaks the immune system into compartments: •CD3: total T cells •CD4: helper T cells •CD8: cytotoxic T cells •CD4/CD8 ratio: immune balance / aging signal •CD19: B cells •CD16/CD56: NK cells This is more useful than a CBC because it shows whether the immune army is balanced — not just whether the total white blood cell count looks normal. 2. NK-cell activity/function assay This gets closer to the real question: Are the NK cells actually killing? NK cells are one of the immune system’s first-line cytotoxic cells. They help identify and eliminate virally infected, stressed, abnormal, or potentially cancerous cells. Counting NK cells is useful, but function matters more. NK cells are recognized for anti-viral and anti-tumor responses, which is why they are a major focus in cancer immunotherapy. 3. Granzyme B + perforin These are the weapons. Perforin helps punch holes in the target cell. Granzyme B enters and helps trigger programmed cell death. So when I think about immune surveillance, I do not just care whether NK cells and CD8+ T cells exist. I care whether they are carrying the cytotoxic machinery needed to do their job. Granzyme B and perforin are central parts of that NK/CD8 killing system. 4. IFN-γ response IFN-γ is a major Th1 / cytotoxic immune signal. This is the “immune system is awake and coordinating an attack” marker. It is produced by NK cells and T cells and helps activate macrophages, antigen presentation, and anti-viral / anti-tumor immune responses. 5. IL-15, IL-15Rα, and IL-7 These are more research-style markers, but they matter for the thesis. IL-15 helps support NK cells and memory CD8+ T cells. IL-15Rα is important because IL-15 often works through receptor-mediated “presentation,” not just floating freely in the blood. IL-7 helps support T-cell survival and immune maintenance. IL-15 is specifically known for regulating activation and proliferation of T cells and NK cells and for helping maintain memory T cells. So IL-15 is not just a “more inflammation” marker. It is closer to an immune-survival and immune-readiness signal. 6. IL-6, TNF-α, and IL-10 These help show the inflammatory background. IL-6 and TNF-α can reflect inflammatory activation. IL-10 is more regulatory / anti-inflammatory. But these are tricky. Higher is not automatically bad, and lower is not automatically good. Timing matters. Context matters. Acute exercise can transiently move cytokines. Chronic inflammation a different story. A CBC tells me the immune system is present. A lymphocyte subset panel tells me how the army is organized. An NK-function assay tells me whether the assassins can actually kill. Granzyme B and perforin tell me whether they are armed. IFN-γ tells me whether the cytotoxic network can communicate. And IL-15 tells me whether the survival and readiness signal may be active. That is the real immune-resilience dashboard. Personal hypothesis. Educational only. Not medical advice, not a diagnosis, and not a claim that any food, supplement, or protocol prevents or treats cancer.
The market is Wonderland. 🕰️🐇 Sometimes you have to believe in six impossible things before the opening bell rings. Impossible thing number one: I’m interested in whether pulsed dietary organosulfur signaling can support the hydrogen-sulfide / persulfidation axis — a redox pathway where sulfur species can modify cysteine residues on proteins and influence metabolic signaling pathways like AMPK. 🧬🔥 The hypothesis: since mechanical exercise already activates AMPK to trigger myokines like IL-15, spiking the upstream redox environment through persulfidation might make that same IL-15-related exercise signal stronger, cleaner, or more sustained. To be clear: this is not a shortcut around training. I still run. The point is not to replace the mechanical signal — it is to explore whether precision nutrition can intensify the biochemical signaling around it. Personal hypothesis. Educational only. Not medical advice, not a recommendation, and not a claim of proven human performance enhancement.
Impossible thing number one: The longevity cuisines from Japan, France, and South Korea may be speaking the same biochemical language. South Korea uses salt, raw garlic, and kimchi. Japan uses Washoku, daikon radish, miso, natto, and green tea. France uses shallots, garlic, fermented cheese, and red wine. Different cuisines. Different cultures. Same recurring pattern: dietary sulfur + fermentation + polyphenols → H₂S / persulfidation biology → AMPK / redox signaling → immune resilience. That does not prove causation. Longevity is never that simple. Medical systems, screening, blood pressure, BMI, smoking rates, and public health all matter. But the overlap is hard to ignore. France gives us the French Paradox version of the signal. The base of traditional French cooking is not just butter. It is the allium family: garlic, onions, shallots, and leeks. Alliums contain organosulfur compounds that can contribute to hydrogen sulfide biology — one of the redox-signaling pathways involved in protein persulfidation and metabolic regulation. Garlic-derived organosulfur compounds have been studied as slow H₂S-releasing agents. Then comes red wine. The point is not “drink wine to live forever.” The point is that red wine polyphenols, especially resveratrol, have long been studied for AMPK/SIRT1-related metabolic signaling. So France may be pulling the same broad lever from another angle: sulfur from alliums, polyphenols from wine, and fermentation from cheese. Japan gives us the sister-study to South Korea. Japan historically had high stomach-cancer pressure from salt-preserved foods, pickled vegetables, H. pylori, and smoked foods. But Japan also built one of the most aggressive gastric-screening cultures in the world, which is a major reason survival is so high. CONCORD-3 data showed Japan’s 5-year net survival for stomach cancer improved to about 60.3% in 2010–2014, while South Korea was even higher at about 68.9%. That matters because the “Korean- Japanese paradox” is probably not one thing. It is not just food. It is not just screening. It is not just genetics. It is the collision of all three! High local gastric stress created high stomach-cancer incidence. Aggressive screening caught cancers earlier. And the broader dietary terrain — fermented foods, alliums, crucifers, soy, sea vegetables, green tea, polyphenols, and sulfur biology — may have supported a more resilient systemic host environment. South Korea may be the most extreme version of this model. The Lancet projection estimated that South Korean women could become the first national female population to cross the 90-year average life expectancy threshold by 2030. The same projection placed France second and Japan third. That is the signal I care about. Not “kimchi cures cancer.” Not “wine is a longevity drug.” Not “natto makes you immortal.” The real thesis is cleaner: The longest-lived food cultures keep repeating the same pattern: sulfur signaling, fermented biology, polyphenols, low metabolic dysfunction, and strong medical infrastructure. Different cuisines. Same biological conversation. Personal hypothesis. Educational only. Not medical advice, not dietary advice, and not a claim that any food prevents or treats cancer.
James Morkert @MorkertJames
22 Followers 109 Following In it for the crypto and day trading of stocks
koop @koop0x
239K Followers 51K Following partner @luckyfun • my telegram channel: https://t.co/KJQudlD3WN
GeneSpaceXplorers🧬... @GeneLearnSpace
815 Followers 3K Following Gene Editing 🧬, Synbio 🌱, Longevity 🧓 , TechBio 🧑🔬, eVOTL 🚁,Humanoid Robots 🤖, Space Exploration 🚀, Exoplanets 🪐, Astronomy 🌌, Space system 🛰 and 👽
Lorie lewis @irisBilla
264 Followers 2K Following spectrum scout // network nomad // purveyor of abstract scifi instruments // sageAI // touchdesigner, openframeworks, blender
Luxi ⭐ @0xLuxi
102K Followers 76K Following Adam 🇺🇸 - Jobless full time influencer - Partner @Tradyxyz - https://t.co/WFVkSbbtJa
Intensive Care Unit A... @ICUAlgorithmLab
255 Followers 2K Following
Baran @Baranznrc
0 Followers 60 Following
Lauren @LaurenNayea
116 Followers 2K Following Dedicated to serving others and giving back to the community. Making a difference in the lives of those in need.
21millionreasons @21millreasons
180 Followers 509 Following
Elena @wsnbc85455381
14 Followers 239 Following
TQ Healthcare Workers... @blueskymindtq
558 Followers 4K Following Love dogs, love the country and am curious about the world! Believes that each of us have to stand up for something worthwhile. A believer in orderly entropy
LogicalValue @LogicalValueMx
175 Followers 853 Following
Dajvavi @Dajvavi
39 Followers 520 Following
LeoSlezak @LeoSlezak135930
197 Followers 1K Following Success is stumbling from failure to failure with no loss of enthusiasm.
steve @sjfischer58
31 Followers 918 Following
AReally @AndreaRilli
80 Followers 1K Following
Rena Conti @contirena1
4K Followers 6K Following health economics & policy biopharmaceutical supply, demand, & innovation
Ildar @Ildar28813994
22 Followers 76 Following
Ahenryokc @ahenryokc
45 Followers 117 Following
Ilfagiolino @AngelInvestor21
77 Followers 459 Following
Klaus Molle @KlausMolle
45 Followers 96 Following
DJ大叔 @DJWANG596944
53 Followers 307 Following
Chas @geographer847
94 Followers 723 Following
Davide Farinati @fari9898
14 Followers 120 Following
BioMedicalRx 🧬 �... @BiomedicalRX
5K Followers 620 Following Life Science investor. No tweets should be construed as investment advice.
Fayez @fayez_issaa
145 Followers 219 Following
Ben @dl01718
83 Followers 812 Following
Atif @chowdhry2000
81 Followers 199 Following
Filedge @filedgeio
9 Followers 185 Following Financial doc intelligence API for agents. Pay-per-call via x402. https://t.co/gzFosM7uGq
moon light @ZShneor47017
23 Followers 393 Following
Robert Glenn @RobertG03181714
164 Followers 1K Following Traveling healthcare worker (cytotechnologist), grandpa to Jack, Razorback fan, nature lover, anti-racism, healthcare for all
Marcos Vexina @marcos_vexina
355 Followers 414 Following
Alfonso @Alfonso1170301
10 Followers 355 Following
Dr. Glenn 🧬🧠�... @CrisprGlenn
3K Followers 7K Following Doctor | Portfolio Manager | MBA | Top 100 Longevity Consultant | CRISPR & Genetic Engineering Specialist | Biohacker | AI & Quantum lead | UAP/UFO Researcher
Red-pilled Rebel @doctorvasan
1K Followers 805 Following CEO, Foundation of Nutritional Science & Metabolic research Author, 1. Protein Paradox: Fix the overload, Find your sweet spot.., 2. MD’s guide to Good Gut.
Elena @wsnbc85455381
14 Followers 239 Following
Lorie lewis @irisBilla
264 Followers 2K Following spectrum scout // network nomad // purveyor of abstract scifi instruments // sageAI // touchdesigner, openframeworks, blender
koop @koop0x
239K Followers 51K Following partner @luckyfun • my telegram channel: https://t.co/KJQudlD3WN
GeneSpaceXplorers🧬... @GeneLearnSpace
815 Followers 3K Following Gene Editing 🧬, Synbio 🌱, Longevity 🧓 , TechBio 🧑🔬, eVOTL 🚁,Humanoid Robots 🤖, Space Exploration 🚀, Exoplanets 🪐, Astronomy 🌌, Space system 🛰 and 👽
Luxi ⭐ @0xLuxi
102K Followers 76K Following Adam 🇺🇸 - Jobless full time influencer - Partner @Tradyxyz - https://t.co/WFVkSbbtJa
Jing Liang 🇺🇦 @AppleHelix
11K Followers 5K Following Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: https://t.co/yDWRnOYAyY https://t.co/SOf8c5OZm6
Banana Oncology @Banana_Oncology
5K Followers 654 Following - Academic/Pharma veteran - Oncology & I/O - Identifying asymmetric bets through scientific/financial deep dives - Not financial advises - Here to learn
Berci Meskó, MD, PhD @Berci
77K Followers 93 Following The Medical Futurist, Author of "Your Map to the Future", Global Keynote Speaker, and Futurist Researcher
Intensive Care Unit A... @ICUAlgorithmLab
255 Followers 2K Following
Dr. Angie Stones/Long... @DrAngieStones1
485 Followers 182 Following I'm a scientist researching consciousness and immortality. My personal interest is longevity. I keep free archive of new research. https://t.co/rCyUIzbddh
Robert Lufkin MD @robertlufkinmd
158K Followers 2K Following Professor and NYT bestselling author of Lies I Taught in Medical School. Metabolic health, longevity & the things your doctor gets wrong.
Ahmed Bennis MD 🫀 @drbennisahmed
5K Followers 781 Following Professor of Cardiology 🫀 FACC / FESC / FHFA
FierceBiotech @FierceBiotech
102K Followers 627 Following The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
21millionreasons @21millreasons
180 Followers 509 Following
Parmita Mishra @parmita
38K Followers 5K Following founder CEO @precigenetic. Scuba diver, engineer, biologist. interested in things that lie deep. // prev. Penn comp bio + Penn Med (cells n epigenomics)
TQ Healthcare Workers... @blueskymindtq
558 Followers 4K Following Love dogs, love the country and am curious about the world! Believes that each of us have to stand up for something worthwhile. A believer in orderly entropy
LogicalValue @LogicalValueMx
175 Followers 853 Following
Dajvavi @Dajvavi
39 Followers 520 Following
LeoSlezak @LeoSlezak135930
197 Followers 1K Following Success is stumbling from failure to failure with no loss of enthusiasm.
steve @sjfischer58
31 Followers 918 Following
Dhaval Kotecha @dhaival_kotecha
13 Followers 247 Following Talk about AdTech & Software companies. Anything I say is NFA!
TJ @MilliqnsWithMe
44 Followers 488 Following | 25 | Documenting my journey to financial freedom with transparent portfolio updates and a few memes along the way. Current portfolio value: $97,381 💸
COINS KID PRIVATE �... @Coins_kidTA
737 Followers 2K Following Only private elite here ‼️. I will mainly talk about crypto,price action analysis etc. ONLY FOR A FEW PEOPLE. 🎯Main account; @Coins_kid
jeymierarugal. @jeymiearugal
146 Followers 2K Following A person's life is very long, and it is not easy to find someone who understands you, so getting married is a very difficult thing for me.
LionsAssetManagement @LionsAssetLLC
2K Followers 2K Following
Art Nalle @ArthurNalle
9K Followers 2K Following Dropped out of grad school to get rich on stocks, crypto and retire at 30, earning a PhD in ZFG.
Sarah Sjogren @PercivalCapital
2K Followers 3K Following The Pepper Potts of Private Portfolio Management
Amy Watson @IRVancouver
26K Followers 8K Following Building cutting-edge investor relations programs that promote positive shareholder engagement and maximum market response. https://t.co/nXCVHJuleR
Grindset Vet @GrindsetVet
4K Followers 2K Following Ancient one, who built a body, business, family & fortune on 100% pure grindset
Stock Spy @Stock_Spy
5K Followers 4K Following Sleuthing for the truth, Stock Spy leaves no stone unturned! https://t.co/CSMxB8qgC6
CascadianTrading @CascadianTrader
7K Followers 6K Following Cascadian Trading is a boutique investment firm specializing in select Canadian stocks and investments of interest to American investors.
Yukon Gold @Yukon_Gold
19K Followers 9K Following Independent Mining and Metals Professional Investor in Silver and Gold
Resources Canada @ResourcesCanada
8K Followers 9K Following Timely, high-impact news, views and analysis from Canada’s natural resource sector
James Hudson @AlphaPortfolios
17K Followers 10K Following AlphaFlight Portfolios Investing in: Diversified deals, special situations and gold stocks. https://t.co/NzKzpruYYC
Hel @Lily677_
123 Followers 440 Following
AReally @AndreaRilli
80 Followers 1K Following
Yair Einhorn @yaireinhorn
19K Followers 50 Following Science and Innovation. I’m laser-focused on BioTech, Pharma, Gene Editing & CRISPR. Occasional thoughts on Stocks, Financial Markets and the Global Economy.Marta Cisneros @Vinoswirl
154 Followers 760 Following My passion for Food and Wine has allowed me to live my dreams and constantly look at what's next. I inspire to be Extraordinary and make a difference.
















